Matching articles for "Spinraza"
Issue 1629 · July 26, 2021 Free
In Brief: Risdiplam (Evrysdi) for Spinal Muscular Atrophy (online only)

Risdiplam ( Evrysdi – Genentech), a survival of motor neuron 2 (SMN2) splicing modifier, has been approved by the FDA for oral treatment of spinal muscular atrophy (SMA) in patients ≥2 months old. It is…

Med Lett Drugs Ther. 2021 Jul 26; 63(1629):e1-2
Risdiplam ( Evrysdi – Genentech), a survival of motor neuron 2 (SMN2) splicing modifier, has been approved by the FDA for oral treatment of spinal muscular atrophy (SMA) in patients ≥2 months old. It is the first oral drug to be approved in the US for treatment of SMA; nusinersen (Spinraza) , an intrathecally administered SMN2-directed antisense oligonucleotide, and onasemnogene abeparvovec (Zolgensma) , an IV adeno-associated virus vector-based gene therapy, were approved earlier.
Issue 1579 · August 26, 2019 Free
Note: Zolgensma Data Manipulation

On August 6, 2019, the FDA issued a statement on data manipulation/inaccuracy issues with Zolgensma , a virus vector-based gene therapy approved for one-time IV treatment of children <2 years old with spinal…

Med Lett Drugs Ther. 2019 Aug 26; 61(1579):129
On August 6, 2019, the FDA issued a statement on data manipulation/inaccuracy issues with Zolgensma , a virus vector-based gene therapy approved for one-time IV treatment of children <2 years old with spinal muscular atrophy. 1 We reviewed Zolgensma in our July 29 issue. 2 According to the FDA statement, the manipulated data pertained to the production process for the product and did not affect the efficacy or safety results from the human clinical trials. It does not require any change in our review. FDA Statement. Statement on data accuracy issues with recently approved gene therapy. Available at: www.fda.gov. Accessed August 15, 2019. Zolgensma – one-time gene therapy for spinal muscular atrophy. Med Lett Drugs Ther 2019; 61:113. Download complete U.S. English article
Issue 1577 · July 29, 2019
Zolgensma - One-Time Gene Therapy for Spinal Muscular Atrophy

The FDA has approved onasemnogene abeparvovec-xioi ( Zolgensma – Avexis), an adeno-associated virus vector-based gene therapy, for one-time IV treatment of children <2 years old who have spinal muscular…

Med Lett Drugs Ther. 2019 Jul 29; 61(1577):113-4
The FDA has approved onasemnogene abeparvovec-xioi ( Zolgensma – Avexis), an adeno-associated virus vector-based gene therapy, for one-time IV treatment of children <2 years old who have spinal muscular atrophy (SMA) and bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. It is the first gene therapy and the second drug to be approved in the US for SMA; nusinersen (Spinraza) was approved in 2016.
Issue 1517 · March 27, 2017
Nusinersen (Spinraza) for Spinal Muscular Atrophy

The FDA has approved nusinersen ( Spinraza – Biogen) for treatment of spinal muscular atrophy (SMA), a hereditary neurodegenerative disease that occurs in about one in every 10,000 births. It is the first…

Med Lett Drugs Ther. 2017 Mar 27; 59(1517):50-2
The FDA has approved nusinersen ( Spinraza – Biogen) for treatment of spinal muscular atrophy (SMA), a hereditary neurodegenerative disease that occurs in about one in every 10,000 births. It is the first drug to be approved in the US for this indication.